Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Compass Therapeutics, Inc. (CMPX : NSDQ)
 
 • Company Description   
Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.

Number of Employees: 24

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.67 Daily Weekly Monthly
20 Day Moving Average: 272,359 shares
Shares Outstanding: 101.28 (millions)
Market Capitalization: $270.43 (millions)
Beta:
52 Week High: $5.92
52 Week Low: $1.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 76.82% 93.75%
12 Week 11.25% 20.71%
Year To Date -15.77% 0.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
80 GUEST STREET SUITE 601
-
BOSTON,MA 02135
USA
ph: 617-500-8099
fax: -
ir@compasstherapeutics.com http://www.compasstherapeutics.com
 
 • General Corporate Information   
Officers
Thomas J. Schuetz - Chief Executive Officer
Vered Bisker-Leib - President and Chief Operating Officer
Carl L. Gordon - Chairman
Phil Ferneau - Director
Steven Squinto - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 20454B104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 101.28
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $270.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.01
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 53.33%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -100.11
12/31/21 - -145.25
09/30/21 - -245.97
ROA
03/31/22 - -87.13
12/31/21 - -118.36
09/30/21 - -176.47
Current Ratio
03/31/22 - 15.03
12/31/21 - 13.84
09/30/21 - 3.72
Quick Ratio
03/31/22 - 15.03
12/31/21 - 13.84
09/30/21 - 3.72
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.33
12/31/21 - 1.43
09/30/21 - 0.39
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©